US Stock MarketDetailed Quotes
ACIU AC Immune
- 4.260
- -0.470-9.94%
Close Jun 14 16:00 ET
421.31MMarket Cap-6218P/E (TTM)
4.686High4.160Low299.98KVolume4.590Open4.730Pre Close1.28MTurnover0.67%Turnover RatioLossP/E (Static)98.90MShares5.14052wk High2.59P/B189.90MFloat Cap1.92052wk Low--Dividend TTM44.58MShs Float19.970Historical High--Div YieldTTM11.12%Amplitude1.680Historical Low4.282Avg Price1Lot Size
AC Immune Stock Forum
Sign in to post a comment
ACI-24.060 represents a cutting-edge approach in the battle against Alzheimer's disease.
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
$AC Immune(ACIU.US$
It's uptrending! Load up now before it's too late! Go Go Go!!!
It's uptrending! Load up now before it's too late! Go Go Go!!!
$AC Immune(ACIU.US$ fly to sky!!!
2
$AC Immune(ACIU.US$
NEWS
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Positive
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expe...
NEWS
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Positive
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expe...
1
$AC Immune(ACIU.US$ Never ceases to amaze me! Yes PM can be a indicator of where the price may go. But so many just don’t realize that BILLIONS of shares trade during regular market hours! So PM you are only seeing a very small fraction of what the true interest or liquidity is in a ticker! So a ticker can jump up huge and then crash during RMH! Or it can jump and fall PM only to climb all day after the market opens! This low liquidity is what makes PM hard to trade!
2
4
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
I Am 102927471 :